Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by G&E Herbal Biotechnology Co., LTD
Information provided by (Responsible Party):
G&E Herbal Biotechnology Co., LTD Identifier:
First received: January 17, 2012
Last updated: February 17, 2016
Last verified: February 2016
This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).

Condition Intervention Phase
Actinic Keratosis
Drug: Vehicle gel
Drug: SR-T100 with 2.3% of SM
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)

Resource links provided by NLM:

Further study details as provided by G&E Herbal Biotechnology Co., LTD:

Primary Outcome Measures:
  • Total clearance rate: [ Time Frame: 8-week post-EOT visit (scheduled at Week 24 visit) ]
    The proportion of patients achieving total clearance of AK lesions in the treatment area (in total of 25cm2 area) at 8-week post-EOT visit (scheduled at Week 24 visit) .

Secondary Outcome Measures:
  • Partial clearance rate [ Time Frame: 24 week ]
    The proportion of patients achieving ≥ 75% total clinically assessed AK lesion counts out of all target lesions in the treatment area (in total of 25cm2 area) at the post-EOT visit (8 weeks after EOT visit).

Estimated Enrollment: 106
Study Start Date: February 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo, gel
placebo comparator
Drug: Vehicle gel
Active Comparator: SR-T100 with 2.3% of SM, gel
2.3% of SM in Solanum undatum plant extract
Drug: SR-T100 with 2.3% of SM
2.3% of SM in Solanum undatum plant extract
Other Name: SR-T100


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female; aged ≥ 18 years old.
  2. Patient who accepts to enter the study by signing written informed consent.
  3. Patient has 4 to 8 clinically diagnosed, discrete, non-hyperkeratotic, non-hypertrophic AK, located with or without a contiguous 25cm2 areas.
  4. Patient allows biopsy to be performed on selected lesion.
  5. Patient agrees to apply the study medication on prescribed treatment area with an occlusive dressing at least 20 hours per day.
  6. Patient agrees photographs to be taken on selected lesion and used as part of the study data package.
  7. Patient in good general health condition (performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG).
  8. Sexually active female patient with child-bearing potential must take reliable contraception method(s) during the participation of the study.

Exclusion Criteria:

  1. Patient with recurrent invasive squamous cell carcinoma (SCC).
  2. Patient has grossly suspicious or inflamed lymph nodes on physical examination.
  3. Patient has evidence of clinically significant or unstable medical conditions.
  4. Patient has any skin condition in the treatment area that may be made worse by treatment.
  5. Patient currently uses or had used on the treatment area(s) OTC retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil (5-FU), imiquimod, topical diclofenac, retinoids, or other topical AK treatments (such as laser abrasion, dermabrasion, glycolic acids, or chemical peels) 28 days prior to screening visit.
  6. Patient had received systemic cancer chemotherapy or immunosuppressant; on the target evaluation area that psoralen plus UVA therapy, UVB therapy were treated 6 months prior to screening visit.
  7. Patient currently uses or has used prednisone and/or prednisolone (≥ 10 mg or the equivalent) more than 2 weeks continuously within 12 weeks prior to randomization visit.
  8. Engaging in activities involving excessive or prolonged exposure to sunlight.
  9. History of allergy or sensitivity to related compounds or other components of the investigational product formulation.
  10. Woman who is pregnant, lactating or planning to become pregnant during the study.
  11. Patient used any investigational drug within 8 weeks prior to the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01516515

Contact: Kou-Wha Kuo, PhD 886-6-505-2976 ext 201
Contact: Hamm-Ming Sheu, MD, MS +886-6-235-3535 ext 5418

United States, California
Moy-Fincher-Chipps Facial Plastics/Dermatology Cedars Sinai Withdrawn
Beverly Hills, California, United States, 90210
Contour Dermatology & Cosmetic Surgery Center Recruiting
Rancho Mirage, California, United States, 92270
Contact: Daniel Rangel    760-778-7799   
Principal Investigator: Timothy M. Jochen, MD         
United States, Colorado
IMMUNOe International Research Centers Recruiting
Longmont, Colorado, United States, 80501
Contact: Bobbi Jo Rhoades    303-771-9000   
Principal Investigator: Todd Becker, MD         
United States, Florida
North Florida Dermatology Associates Withdrawn
Jacksonville, Florida, United States, 32204
Park Avenue Dermatology Withdrawn
Orange Park, Florida, United States, 32073
Atlantic Clinical Research Collaborative Recruiting
West Palm Beach, Florida, United States, 33406
Contact: Cristina Iparraguirre    561-964-6664   
Principal Investigator: Barry Kuttner, MD         
Palm Beach Research Center Recruiting
West Palm Beach, Florida, United States, 33409
Contact: Annette Pitts, MD    561-689-0606   
Principal Investigator: John Goodman, MD         
United States, Michigan
Grekin Skin Institute Withdrawn
Warren, Michigan, United States, 48088
United States, North Carolina
Wake Research Associates Withdrawn
Raleigh, North Carolina, United States, 27612
United States, Texas
Suzanne Bruce and Associates,P.A. The Center for Skin Research Recruiting
Katy, Texas, United States, 77056
Contact: Jasmine Leung, MD    832-858-3050   
Principal Investigator: Suzanne Bruce, MD         
Pflugerville Dermatology Clinical Research Recruiting
Pflugerville, Texas, United States, 78660
Contact: Patricia Lewis    512-279-2545   
Principal Investigator: Edward L. Lain, MD         
Dermatology Clinical Research Center of San Antonio Withdrawn
San Antonio, Texas, United States, 78229
United States, Virginia
The Education & Research Foundation, Inc Recruiting
Lynchburg, Virginia, United States, 24501
Contact: Sue Foster    434-847-8400 ext 103   
Principal Investigator: David C. Wilson, MD         
United States, Washington
Premier Clinical Research Recruiting
Spokane, Washington, United States, 99204
Contact: Kathryn Bland, MD    509-343-3710   
Principal Investigator: William P Werschler, MD         
Sponsors and Collaborators
G&E Herbal Biotechnology Co., LTD
  More Information

Responsible Party: G&E Herbal Biotechnology Co., LTD Identifier: NCT01516515     History of Changes
Other Study ID Numbers: GESRTAKB
Study First Received: January 17, 2012
Last Updated: February 17, 2016

Keywords provided by G&E Herbal Biotechnology Co., LTD:
Actinic Keratosis

Additional relevant MeSH terms:
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms processed this record on May 25, 2017